Home>Topics>Stocks>Momenta Pharmaceuticals

Momenta Pharmaceuticals MNTA

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Generics want to go after Copaxone now

      Headlines

      Tue, 15 Apr 2014

      Teva failed to show that it would suffer "irreparable harm" if the stay was not issued. The Court could announce its decision at any time. A ruling on the case might not happen until mid-2015. ( NVS ) ( MYL ) ( MNTA ) Post your comment!

    2. Teva asks the Supreme Court to block competitors

      Headlines

      Mon, 7 Apr 2014

      accepted the case on March 31 but will not hear oral arguments until October and a ruling might not happen until mid-2015. Teva believes it will suffer "irreparable harm" if other generics are allowed to market. ( MNTA ) Post your comment!

    3. Midday Gainers / Losers

      Headlines

      Mon, 31 Mar 2014

      PACB +13% . INSM +13% . BLDR +13% . CWEI +12% . ASTM +12% . OMED +12% . Top 10 Losers: WHX -27% . MNKD -15% . MNTA -15% . GPRC -15% . FATE -13% . OTC:PFIE -13% . OTCPK:MRNA -12% . UTIW -9% . SORL -9% . OBCI -8% . Post your

    4. Momenta sinks on Supreme Court decision

      Headlines

      Mon, 31 Mar 2014

      Shares of generic drug maker Momenta Pharmaceuticals ( MNTA -11.4% ) are down in early trading after the Supreme Court agrees to hear Teva's ( TEVA +4.7% ) appeal of a lower court

    5. U.S. Supreme Court Decision is Minor Plus for Teva

      Commentary

      Mon, 31 Mar 2014

      Likewise, the news is a slight negative for two of the major contenders attempting a generic Copaxone: Momenta Pharmaceuticals and Mylan. Negative shifts in our fair value estimates for both of these companies from potential generic

    6. New Morningstar Analyst Report for Momenta Pharmaceuticals , Inc.

      Stock Reports

      Mon, 10 Feb 2014

      Increasing pharmaceutical complexity shines light on Momenta's capabilities.

    7. Momenta Awaits Potential Generic Copaxone Decision

      Commentary

      Wed, 6 Nov 2013

      We’re leaving our fair value estimate for Momenta Pharmaceuticals unchanged after the company reported third-quarter results within our expectations. Momenta reported a net loss of $25.4 million

    8. Patent Litigation Creates Earlier-Than-Expected Generic Copaxone Launch Opportunity

      Commentary

      Fri, 2 Aug 2013

      We're raising our fair value estimate for Momenta Pharmaceuticals to $16 per share after updating our forecast for a potential generic Copaxone launch to 2014 from 2015 following the recent U

    9. Teva Faces Patent Setback on Copaxone Following Momenta and Mylan Appeal

      Commentary

      Fri, 26 Jul 2013

      decision is a positive for the two major contenders attempting to manufacture generic versions of Copaxone, Mylan MYL and Momenta MNTA . We may slightly increase our fair value estimates for both of these firms as we reevaluate our assumptions. We plan to adjust

    10. Competition in Generic Lovenox Market Remains Headwind for Momenta in 2013

      Commentary

      Tue, 30 Apr 2013

      Momenta Pharmaceutical's MNTA first-quarter results mostly met our expectations, but volatility from market share shifts and pricing pressure in the generic

    « Prev12345Next »
    Content Partners